New SGLT-2 Inhibitor – Ertugliflozin
New SGLT-2 Inhibitor – Ertugliflozin
The Food and Drug Administration (FDA) has approved Ertugliflozin (Steglatro), a new SGLT-2 Inhibitor to treat adults with type 2 diabetes. Also approved are two new combination medications with ertugliflozin. These include Segluromet (ertugliflozin plus metformin) and Steglujan (ertugliflozin plus sitagliptin). See box below for available combination doses (in mgs).
Dosing range: 5 -15 mg daily. Monitor GFR before starting. Don’t start med if GFR is less than 60 and stop if GFR is less than 30.
Considerations: Ertugliflozin has the same warnings as other SGLT-2s: Watch for hypotension, UTI’s, increased urination, genital infections, ketoacidosis.
Benefits: no hypoglyecmia or weight gain.
Lowers A1c 1.0% – 2.0%. Lowers wt 1-3 lbs.
Download our FREE Updated Insulin PocketCard
Medication Update Webinar – Feb 19, 2018 11:30 to 1pm (PST)
Feeling overwhelmed by all the new recently approved diabetes medications? Two bio-similiar insulins are now available and another GLP-1 RA was just approved. Plus, 2 new combo oral meds are now available.
Are you wondering how to apply the new 2018 ADA and AACE Medication Management Guidelines into practice?
We are here to help out!
This webinar will discuss how to integrate these new medications into our practice. We will discuss the benefits and limitations and critical information to share with our patients and providers.
If you want cutting edge information on the latest pharmacology and how to incorporate the new ADA Guidelines into practice, we highly recommend this Meds Update.
To Join Us and earn CEs you have 2 options:
![](/wp-content/uploads/2023/01/insta-png-v5.png")
